As laboratories consider expanding patient testing capabilities to include antibody testing for SARS-CoV-2, significant unknowns related to testing remain. Concerns range from uncertainty of the accuracy of many commercially available serologic assays to the clinical significance of positive results.
In this webinar, we will discuss this guidance, as well as the difference between the clinical impact of an antibody test result versus a molecular test result. Attendees will gain insights into the regulatory pathway and secure helpful advice on how to implement serologic testing.
- Neil Anderson, MD, FCAP
- Elitza S. Theel, Ph.D., D(ABMM)